Homozygous Familial Hypercholesterolemia in Spain: Data From Registry of the Spanish Atherosclerosis Society
The Journal of Clinical Endocrinology & Metabolism · 15.07.2025 · 110 (8) · 2280-2287
DOI: 10.1210/clinem/dgae784 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 08.11.2024. Verfasst von Rosa M Sánchez-Hernández und 13 weiteren Autor:innen. Beteiligte Einrichtung: Sección de Endocrinología y Nutrición, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Instituto Universitario de Inves…. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Atherosclerosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Instituto de Salud Carlos III (ISCIII), Ultragenyx.
Abstract (Originalsprache)
Context
Homozygous familial hypercholesterolemia (HoFH) is a rare disease characterized by the presence of 2 pathogenic variants in the LDLR, APOB, PCSK9, or LDLRAP1 genes, which cause very high levels of LDL-cholesterol and premature atherosclerotic cardiovascular disease (ASCVD).
Objective
To analyze the current situation regarding diagnosis, cardiovascular disease, lipid-lowering treatment, and degree of control of lipids in patients with HoFH in the National Dyslipidemia Registry of the Spanish Atherosclerosis Society.
Methods
Subjects with HoFH, confirmed by the presence of 2 pathogenic variants in the genes mentioned above, included in the registry from 2013 to June 2023 with an updated review were analyzed.
Results
Of 71 included subjects with HoFH, 40.8% were women, aged 52 [24-62] years, 57 adults and 13 children. The median follow-up was 7 [4-13] years. Age of diagnosis was 14 [2-26] years, with 10% of ASCVD at diagnosis and 27% of current ASCVD at 40.6 (13.4) years of age; 38% were on PCSK9 inhibitors, 9 patients on lomitapide, 9 on LDL apheresis, and 1 patient on evinacumab. Subjects with more than 4 therapies achieved >80% reduction in LDLc. In the last visit, the median LDLc was 139.3 [89.4-204.2] mg/dL. ASCVD was strongly associated with male sex and family history of ASCVD, relative risk 5.26 (1.53-18.10) and 2.53 (1.03-6.26), P < .05, respectively. Only 18% and 10% meet the recommended LDLc goal in primary and secondary prevention respectively.
Conclusion
The current situation of HoFH in Spain is better than expected, with marked reductions in LDLc levels with new treatments. In this population, recommended LDLc goals are difficult to achieve despite maximum lipid-lowering therapy. ASCVD has been reduced and delayed by 2 decades.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sección de Endocrinología y Nutrición, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Instituto Universitario de Investigaciones Biomédicas y Sanitarias de la Universidad de Las Palmas de…
- Universitat Rovira i Virgili, Unidad de Medicina Vascular y Metabolismo, Unitat de Recerca Lipids i Arteriosclerosi, Hospital Universitari Sant Joan, IISPV: CIBERDEM, Reus 43204, Spain.
- Unidad de Lípidos y Arteriosclerosis, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/Hospital Universitario Reina Sofia/Universidad de Córdoba, Córdoba 14004, Spain.
- Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario de Valencia- INCLIVA, Departamento de Medicina, Univerdad de Valencia, Valencia 46010, Spain.
- CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Madrid 28029, Spain.
- Hospital Universitario 12 de Octubre, Servicio de Medicina Interna, Unidad de Lípidos y Arteriosclerosis, Madrid 28041, Spain.
ORCID-Profile: Rosa M Sánchez-Hernández, Luis Masana, Fernando Civeira
Förderung
- Instituto de Salud Carlos III (ISCIII)
- Ultragenyx
Zitieren
APA
Sánchez-Hernández, R. M., Ibarretxe, D., Fuentes Jiménez, F., Martínez-Hervás, S., Blanco-Echevarría, A., Cortés Rodríguez, B., Rodríguez-Carnero, G., Martín Ordiales, M. M., Pérez, A., González-Bustos, P., Argüeso Armesto, R., Sánchez-Sobrino, P., Masana, L., & Civeira, F. (2025). Homozygous Familial Hypercholesterolemia in Spain: Data From Registry of the Spanish Atherosclerosis Society. The Journal of Clinical Endocrinology & Metabolism, 110(8), 2280-2287. https://doi.org/10.1210/clinem/dgae784
Vancouver
Sánchez-Hernández RM, Ibarretxe D, Fuentes Jiménez F, Martínez-Hervás S, Blanco-Echevarría A, Cortés Rodríguez B, et al. Homozygous Familial Hypercholesterolemia in Spain: Data From Registry of the Spanish Atherosclerosis Society. The Journal of Clinical Endocrinology & Metabolism. 2025;110(8):2280-2287. doi:10.1210/clinem/dgae784
BibTeX
@article{SnchezHernndez2025,
author = {Sánchez-Hernández, Rosa M and Ibarretxe, Daiana and Fuentes Jiménez, Francisco and Martínez-Hervás, Sergio and Blanco-Echevarría, Agustín and Cortés Rodríguez, Begoña and Rodríguez-Carnero, Gemma and Martín Ordiales, María Mercedes and Pérez, Antonio and González-Bustos, Pablo and Argüeso Armesto, Rosa and Sánchez-Sobrino, Paula and Masana, Luis and Civeira, Fernando},
title = {Homozygous Familial Hypercholesterolemia in Spain: Data From Registry of the Spanish Atherosclerosis Society},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {8},
pages = {2280--2287},
doi = {10.1210/clinem/dgae784}
}
EUVIMED